Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
Conditions
Brief summary
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.
Detailed description
Part A of the trial will consist of two cohorts, one dosed every 2 weeks and one dosed every 3 weeks in a standard 3+3 design. Part A is the dose finding portion of the trial. 18 to 36 participants will be enrolled. Part B consists of 3 cohorts: Cohort A is for patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma. Patients will receive TST001 at 2mg/kg or 4mg/kg Q2W plus Nivolumab and mFOLFOX6. Alternative allocation of patients between the 2 doses will be performed. The first 6 patients at each dose level as the lead-in phase will not be selected on the basis of their tumor's CLDN18.2 expression. Approximately 12-42 patients will be enrolled in Cohort A. Cohort B is for patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies. Patient will receive TST001 plus Nivolumab. No selection based on CLDN18.2 expression will be required for the safety run-in (3-6 patients). Patients with CLDN18.2 expression in tumor tissue tested by the central laboratory will be enrolled in the expansion phase. Safety run-in phase will follow 3+3 rule with two dose levels, TST001 3mg/kg and 6mg/kg Q3W combined with nivolumab. Approximately 30 patients will be enrolled in Cohort B including the patients in the safety run-in phase. Cohort C is for patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma; Patients will receive TST001 at 2mg/kg or 4mg/kg Q2W plus gemcitabine and albumin-bound paclitaxel. Alternative allocation of patients between the 2 doses will be performed. The first 6 patients at each dose level as the lead-in phase will not be selected on the basis of their tumor's CLDN18.2 expression. Approximately 12-42 patients will be enrolled in Cohort C.
Interventions
DRUGTST001
TST001 is a humanized IgG1 monoclonal antibody.
Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
DRUGmFOLFOX6
mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
DRUGGemcitabine
Chemotherapy medication
DRUGAlbumin-Bound Paclitaxel
Chemotherapy medication
Sponsors
Bristol-Myers Squibb
Suzhou Transcenta Therapeutics Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Part A - 2 arms, Q2w and Q3w, 3+3 design dose escalation; Part B - dose expansion, 3 Cohorts
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female ≥ 18 years. * Patients with histologically or cytologically confirmed, locally advanced or metastatic solid tumors. Part A only: \* Patients must be: a) progressed after standard therapies, b) intolerant of standard therapies, or c) with a tumor type without standard therapy. Part B only: * Cohort A: Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received one infusion of mFOLFOX6 plus nivolumab during the screening period. * Cohort B: Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies; adjuvant or neoadjuvant therapy could be regarded as one line of therapy only if disease progressed or recurred during these treatments or within 6 months or less after completion of these treatments. * Cohort C: Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received up to 2 infusions of Gemcitabine + albumin-bound paclitaxel (with one week between each infusion) during the screening period. * Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0-1 . * Patients with adequate cardiac, liver, renal function, etc.
Exclusion criteria
* Symptomatic central nervous system metastases. * Prior treatment with any CLDN18.2 target agents * Allergy or sensitivity to TST001 or known allergies to comparable drugs * Documented history of multiple other allergies requiring interventions * Severe cardiovascular disease, including CVA, TIA, myocardial infarction, or unstable angina, NYHA class III or IV heart failure or uncontrolled arrhythmia within 6 months of study entry, severe QTc prolongation, concomitant risks for QTc prolongation. * Concurrent malignancy within 5 years prior to entry except adequately treated certain types of cancer * Active and clinically significant infections, known uncontrolled infections with hepatitis B, hepatitis C, known human immunodeficiency virus with acquired immunodeficiency syndrome related illness * Any condition that the investigator or primary physician believes may not be appropriate for participating in the study. Other protocol-defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participant Safety as characterized by frequency and severity of adverse events | up to 100 days following last dose | Characterization of TST001 safety profile including frequency and severity of adverse events that are related to treatment. |
| Maximum Tolerated Dose (MTD or Recommended Phase 2 Dose (RP2D) | up to 100 days following last dose | As measured by number of participants experiencing dose related toxicity (DLT) in each escalating cohort |
| Participant Safety and Tolerability of TST001 in combination with Nivolumab as characterized by frequency and severity of adverse events | Up to 100 days following last dose | Characterization of TST001 + Nivolumab safety profile including frequency and severity of adverse events that are related to treatment. |
| Participant Safety and Tolerability of TST001 in combination with Nivolumab and mFOLFOX6 as characterized by frequency and severity of adverse events | Up to 100 days following last dose | Characterization of TST001 + Nivolumab + mFOLFOX6 safety profile including frequency and severity of adverse events that are related to treatment. |
| Participant Safety and Tolerability of TST001 in combination with gemcitabine and albumin-bound paclitaxel as characterized by frequency and severity of adverse events | Up to 100 days following last dose | Characterization of TST001 + Gemcitabine + albumin-bound paclitaxel safety profile including frequency and severity of adverse events that are related to treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity | up to 30 days following last dose | by measurement of Incidence of anti-drug antibodies (ADA) |
| PK | Up to 30 days following last dose | time to reach maximum serum concentration (Tmax) |
| Objective response rate (ORR) | up to 24 months, until disease progression or start of another anti-cancer therapy | as measured by RECIST 1.1 |
| Duration of Response (DOR) | up to 24 months, until disease progression or start of another anti-cancer therapy | duration of response (DOR) |
| Progression free survival (PFS) | up to 24 months, until disease progression or start of another anti-cancer therapy | as measured by RECIST v1.1 |
| PK parameters | Up to 30 days following last dose | Maximum serum concentration (Cmax) |
Countries
United States
Outcome results
None listed